MedTrace Logo

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

NCT02978781 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-11-28

Study results available
· View outcomes & findings →

Summary

This study is a three-part, multicenter, Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in adult participants with essential tremor.

Conditions

Interventions

DRUG

SAGE-217

SAGE-217 Oral Solution

DRUG

SAGE-217

SAGE-217 Capsules

DRUG

Placebo

SAGE-217 matching placebo capsules

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-24
Primary Completion
2017-11-22
Completion
2017-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02978781 on ClinicalTrials.gov